Thursday, May 16, 2013

Theralase Advanced Cancer Therapy Research Recognized at Major International Conference

Toronto, Ontario – May 16, 2013, Theralase Technologies Inc. (TSXV: TLT) (“Theralase”) announced today that its researchers have discovered a significant new mechanism of action for a new class of Photo Dynamic Compounds (PDCs), that have been custom designed to destroy cancer cells when activated by a proprietary light source.

The preclinical study, conducted by Theralase scientists and their colleagues at University Health Network’s Princess Margaret Cancer Centre, was presented on May 15, at the Laser World of Photonics conference held in Munich, Germany.

In previous preclinical studies, Theralase’s PDCs have been proven to be promising anti-cancer agents in various cancer models. Their efficacy involved a number of critical cellular processes, including DNA damage and programmed cell death. All PDCs were thought to work primarily by oxygen-dependent mechanisms, ultimately causing cell death in the presence of highly reactive oxygen. In this study; however, scientists established that a new class of Theralase PDCs have an additional “oxygen independent” mechanism of action, which would increase efficacy in the destruction of more clinically aggressive tumours.

The research lead by Dr. Lothar Lilge, Senior Scientist, Ontario Cancer Institute, Princess Margaret Cancer Centre and Dr. Arkady Mandel, Chief Scientific Officer, Theralase has shown that specific metal-based PDCs when tested for effectiveness of cancer destruction in a low oxygen environment were proven to be highly effective in the destruction of human brain cancer cells in-vitro, thus activating this newly discovered pathway. Additionally using this pathway, Theralase scientists confirmed in a preclinical model a complete response rate and the destruction of subcutaneous (under the skin) colon cancer tumours in mice, which were treated with Theralase’s anti-cancer PDC technology. On follow-up, the initial complete response was maintained in two-thirds of the animals for over 1 year without recurrence.

Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. stated, “Recognition of our world class anti-cancer research at the Munich conference is another testament to the cutting edge research our scientists are conducting in this field. Our findings would strongly suggest that Theralase’s PDCs oxygen independent potency would significantly enhance our ability to destroy cancer cells. Tumours in a low oxygen environment have been extremely challenging because this lack of oxygen renders solid tumours much more resistant to therapeutic interventions. Many traditional therapeutic agents, conducted on poorly oxygenated solid core tumours, including any currently FDA approved PDCs, are susceptible to a “self-limiting” activity; whereby, below a critical threshold oxygenation level, their efficacy is progressively reduced resulting in minimal to no cancer cell destruction. This new class of Theralase PDCs are not susceptible to this “self-limiting” activity and as a result maintain their efficacy even in extremely low oxygenated cancerous tumours, such as breast and prostate cancer. As a result, Theralase is extremely excited about the latest research and what it means in the field of cancer destruction. Theralase is committed to the early commercialization of its patented light activated Photo Dynamic Compounds in the areas of anti-cancer and anti-bacterial applications to generate substantial revenues for the Company and hence dramatically increase shareholder value.”

About Theralase Technologies Inc.

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary laser technology.

For further information please visit , regulatory filings may be viewed by visiting

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:

Roger Dumoulin-White,                                                                      
President & CEO                                                                                  
416-699-LASE (5273) ext. 225                                                              

Kristina Hachey
Chief Financial Officer
416-699-LASE (5273) ext. 224                                                                     

Greg Bewsh
Director of Investor Relations
416-699-LASE (5273) ext. 258

Arkady Mandel
Chief Scientific Officer
416-699-LASE (5273) ext. 260

1 comment:

  1. Sound therapy is a blend of different sound formulas which are produced by many sound emitting tools which can heal diseases as common as cold to as difficult to cure diseases like cancer, Alzheimer’s, Parkinson’s etc.
    Sound therapy is effective in Cancer healing effectively and rapidly. It can also assist in healing if the patient is under any medical treatment for Acute Sinusitis.